 Moderna Inc. MRNA, -0.68 shares rallied in the extended session Tuesday after the biotech drug company said results from a late-stage clinical trial for its respiratory virus vaccine met endpoints, and that it will submit for Food and Drug Administration approval by mid-2023. Moderna shares surged as much as 5 after hours, following a 0.7 decline to close the regular session at 190.69. 